Neola Medical AB (OSTO:NEOLA) Research & Development: kr0.00 Mil (TTM As of Dec. 2025)


OSTO:NEOLA Neola Medical AB OSTO:NEOLA
29 GF Score
Price kr0.88
! 1 Warning Sign
View Full Analysis

What is Neola Medical AB Research & Development?

Neola Medical AB OSTO:NEOLA 29 Research & Development is kr0.00 Mil as of Dec. 2025. GuruFocus rates OSTO:NEOLA with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Neola Medical AB's Research & Development for the three months ended in Dec. 2025 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.00 Mil.

Neola Medical AB  (OSTO:NEOLA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Neola Medical AB Research & Development Related Terms

Neola Medical AB Research & Development Historical Data

* Premium members only.

The historical data trend for Neola Medical AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neola Medical AB Research & Development Chart

Neola Medical AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Neola Medical AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:NEOLA
29GF Score
Neola Medical AB OSTO:NEOLA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neola Medical AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Neola Medical AB (OSTO:NEOLA) has a Research & Development of kr0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Neola Medical AB and its competitors.
Is Neola Medical AB's Research & Development too high?
Neola Medical AB's current Research & Development is kr0.00 Mil. Overall, Neola Medical AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Neola Medical AB's Research & Development compare to ABT and SYK?
Neola Medical AB's Research & Development of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Neola Medical AB and its competitors. Neola Medical AB's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neola Medical AB stock overvalued right now?
Neola Medical AB (OSTO:NEOLA) has a current Research & Development of kr0.00 Mil. The current Research & Development is kr0.00 Mil. Neola Medical AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Neola Medical AB (OSTO:NEOLA), the current Research & Development is kr0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neola Medical AB Business Description

Address Scheelevagen 27, Ideon Science Park, Gateway 9th fl oor, Lund, SWE, 223 63
Neola Medical AB is revolutionizing neonatal intensive care with NEOLA, a medical device that can offer continuous lung monitoring and real-time alerts of life-threatening complications using a technology that measures lung volume changes and oxygen gas concentration. NEOLA has the potential to provide care, fewer days in intensive care, and healthier lives for preterm born infants. The company is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to health care.
29GF Score

Get the complete analysis for OSTO:NEOLA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.88
Price